Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease (PVNIM)

July 19, 2023 updated by: Association HGE CHU Bordeaux Sud

Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.

The aim of this retrospective and prospective study is to evaluate the 20-year prognosis value of non-invasive methods for the diagnosis of chronic liver disease for predicting survival and complications of cirrhosis.

Study Overview

Status

Recruiting

Conditions

Detailed Description

All consecutive patients with chronic liver disease will be followed during 20 years.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all consecutive patients with an age over eighteen and chronic liver disease

Description

Inclusion Criteria:

  • chronic hepatitis C
  • chronic hepatitis B
  • alcohol liver disease
  • non alcoholic liver disease

Exclusion Criteria:

  • ascitis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Chronic liver disease
all patients with chronic liver disease followed using non-invasive methods

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overall survival
Time Frame: 20 years
20 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Survival without liver complications
Time Frame: 20 years
20 years

Other Outcome Measures

Outcome Measure
Time Frame
Survival without liver transplantation
Time Frame: 20 years
20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Association HGE CHU Bordeaux Sud

Investigators

  • Study Chair: Faiza Chermak, MD, Association HGE CHU Bordeaux Sud
  • Study Chair: Jean-Baptiste Hiriart, MD, Association HGE CHU Bordeaux Sud
  • Study Chair: Juliette Foucher, MD, Association HGE CHU Bordeaux Sud
  • Study Director: Victor de Lédinghen, MD, PhD, Association HGE CHU Bordeaux Sud

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2014

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

February 1, 2034

Study Registration Dates

First Submitted

February 11, 2014

First Submitted That Met QC Criteria

February 11, 2014

First Posted (Estimated)

February 12, 2014

Study Record Updates

Last Update Posted (Actual)

July 20, 2023

Last Update Submitted That Met QC Criteria

July 19, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HL V-0214

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Liver Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe